Interferon regulatory factor 5 (IRF5) is a transcription factor activated downstream of Toll-like receptors (TLRs) 7, 8 and 9, and is predominantly expressed in dendritic cells, B cells, monocytes and ...
Kymera Therapeutics has announced the launch of a new program targeting the IRF5 transcription factor, enhancing its portfolio of oral immunology treatments for autoimmune and rheumatic diseases. The ...
BOSTON, June 25, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart ...